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Accumulation of collagen is the major pathologic fea­
ture in a variety of fibrotic processes, including dermal 
fibrosis in progressive systemic sclerosis, morphea, fa­
milial cutaneous collagenoma, connective tissue nevi of 
the collagen type and in keloids. Recent advances in the 
biochemistry of collagen have allowed us to define spe­
cific levels of collagen biosynthesis and degradation at 
which a pharmacologic intervention can lead to reduced 
collagen deposition. In this review, we are discussing the 
mechanisms of action by some of the therapeutic agents 
currently in use. We further present some new develop­
ments involving amino acids and their analogues which 
could potentially provide us with novel means to reduce 
the excessive accumulation of collagen in dermal fibrotic 
processes. 
Excessive accumulation of collagen is the major pathologic 
feature in a variety of clinical conditions characterized by tissue 
fibrosis. These conditions include localized processes, as for 
example, pulmonary fibrosis and liver cirrhosis, or more gen­
eralized processes, like progressive systemic sclerosis [1-3]. 
Collagen deposition is a feature of different forms of dermal 
fibrosis, which in addition to scleroderma, include localized and 
generalized morphea, keloids, hypertrophic scars, familial cu­
taneous collagenoma and connective tissue nevi of the collagen 
type [3-7]. Recent advances in the understanding of the normal 
biochemistry of collagen [8,9] have allowed us to define specific 
levels of collagen biosynthesis and degradation at which a 
pharmacologic intervention could lead to reduced collagen dep­
osition in the tissues. In this overview, we will discuss initially 
the mechanisms of action by some of the therapeutic agents, 
many of which are currently in use for treatment of collagen 
accumulation diseases. We further present some new develop­
ments involving amino acids, or their analogues, which interfere 
with collagen production by isolated cells or tissues under 
experimental conditions. In the future these compounds could 
potentially provide us with novel means to reduce the excessive 
collagen accumulation in diseases. 
This work was supported by United States Public Health Service, 
National Institutes of Health grants AM-28450 and GM-28833, and by 
a grant from the March of Dimes-Birth Defects Foundation. Dr. Uitto 
is recipient of Research Career Development Award 5-K04-AM-0897, 
and Dr. Ryhiinen is recipient of New Investigator Research Award AG-
03172, both from National Institutes of Health. 
Abbreviations: 
pC-Collagen refers to a collagen precursor whose amino-terminal 
extension has been removed while the carboxy-terminal extension 
is still present on the molecule; the carboxy-terminus is subse­
quently cleaved by procollagen C-proteinase. Correspondingly, 
pN-collagen denotes a precursor molecule whose carboxy-terminal 
extension has been cleaved but the amino-terminal extension 
remains uncleaved. 
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NORMAL BIOSYNTHESIS AND DEGRADATION OF 
COLLAGEN 
The metabolism of collagen in normal tissues is a complex 
process involving a careful balance between biosynthesis and 
degradation (Table I). The biosynthetic pathway consists of 
several steps, many of which are unique to collagen (Fig 1). 
Many of these steps are also catalyzed by specific enzymes 
whose activities are stringently modulated by several factors 
(Table II) [3,10]. 
The biosynthetic pathway of collagen is initiated by the 
transcription of the genetic information from a collagen gene to 
the precursors of messenger RNA (Table I). After extensive 
processing, including "splicing," "capping," polyadenylation, 
etc., the functional messenger RNA can serve as a template for 
translation [3]. The translation of pro collagen messenger RNA 
takes place on the membranes of the rough endoplasmic retic­
ulum of collagen-producing cells, such as fibroblasts. The initial 
translation product contains a transient peptide sequence, so­
called "signal" -peptide, which is removed cotranslationally. 
After the removal of the signal sequence, the newly-synthesized 
polypeptide chains of the collagen precursor, procollagen, are 
vectorially released in the lumen of the rough endoplasmic 
reticulum. Intracellularly, these polypeptides, known as pro-a 
chains, undergo extensive co- or posttranslational modifica­
tions, and most of these reactions are catalyzed by specific 
enzymes [1,3,10]; these reactions include the synthesis of 3- and 
4-hydroxyproline, hydroxylysine and hydroxylysine-O-glyco­
sides (Table I). The hydroxylated and glycosylated pro-a chains 
associate, become linked by disulfide bonds, and fold into a 
triple-helical conformation (Fig 1). This precursor form of col­
lagen, procollagen, contains noncollagenous peptide extensions, 
so-called propeptides, at both the amino- and the carboxyter­
minal ends of the molecule. Subsequently, the procollagen 
molecules are transported through Golgi vesicles into the extra­
cellular space. Here, several additional posttranslational reac­
tions take place: The propeptides are cleaved by at least 2 
specific endopeptidases, procollagen N-proteinase and C-pro­
teinase, which remove the amino- and carboxy-terminal peptide 
extensions from procollagen, respectively. After the removal of 
the extension peptides, individual collagen molecules align into 
microfibrillar structures; the association of microfibriIs then 
leads to formation of collagen fibers in the tissues (Fig 1). The 
fiber structures are stabilized by the formation of covalent 
lysine- and hydroxylysine-derived intermolecular cross-links. 
Oxidative deamination of some lysyl and hydroxylysyl residues 
by lysyl oxidase precedes the formation of these cross-links. 
The triple-helical collagen molecules are remarkably resis­
tant to proteolysis by most tissue proteinases, and the removal 
of collagen fibers in tissues is initiated only by a group of 
enzymes, known as collagenases (Fig 2). The vertebrate colla­
genases are metalloproteinases, and they cleave triple-helical 
collagen molecules at a specific site; the cleavage sequences in 
interstitial collagens have been shown to be glycine-isoleucine 
or glycine-leucine. After the initial cleavage by a collagenase, 
the cleavage products denature at body temperatures and be­
come susceptible to degradation by a variety of proteolytic 
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TABLE I. Major steps in the biogenesis and degradation of collagen, their functional significance and modulating factors 
Step" 
I. Expression of Genes Coding for Col­
lagen polypeptides 
a. Gene selection 
b. Transcription 
c. Processing of mRNA precursor 
d. Translation 
e. Control of the rate of transcription, 
mRNA processing or translation 
II. Intracellular Co- and Post-transla­
tional Modifications 
a. Removal of the signal sequence 
b. Synthesis of 4-hydroxyproline 
c. Synthesis of 3-hydroxyproline 
d. Synthesis of hydroxylysine 
e. Synthesis of hydroxylysine-O-gly­
cosides 
f. Glycosylation of the extension pep­
tides 
g. Degradation of non helical chains 
h. Chain association and disulfide 
bonding 
i. Triple-helix formation 
III. Secretion 
IV. Extracellular Modifications 
a. Removal of the extension peptides 
from pro collagen 
b. Deamination of certain lysine and 
hydroxy lysine residues 
c. Non-enzymatic glucosylation 
V. Fiber Formation 
a. Alignment of the molecules 
b. Formation of cross-links 
c. Supramolecular assembly 
d. Interactions with other extracellu­
lar macromolecules 
VI. Extracellular Degradation 
a. Cleavage by specific collagenases 
b. Further degradation by peptidases 
and enzymes metabolizing free 
amino acids 
Functional significance 
Determines the collagen isotype to be syn-
thesized 
Formation of mRNA precursor 
Formation of functional mRNA 
Assembly of polypeptide chains 
Determines the amount of polypeptides 
synthesized 
May be necessary for secretion 
Stabilization of triple-helix 
Unknown 
Stabilization of covalent cross-links; attach­
ment site for glycosylation 
May influence cross-link formation and de­
termine the morphology and stability of 
the fibers 
Unknown 
Removal of defective polypeptides and 
modulation of collagen production 
Facilitation of the triple-helix formation 
Pre-requisite for proper secretion 
Transport of procollagen through Golgi ap­
paratus to .the extracellular space 
Necessary for fiber formation 
Necessary for cross-link formation 
May interfere with fiber formation 
Formation of microfibrils 
Stabilization of the fiber structures 
Architectural organization of collagen in tis-
sues 
Determines the physiologic properties of 
tissues 
Rate-limiting step in degradation 
Removal of degradation products 
Modulating factors 
Bromodeoxyuridine, environmental factors 
Glucocorticosteroids, possibly other hormones 
None known 
Feed-back inhibition by extension peptides 
Same as Ib and d 
Amino acid analogues, such as hydroxynorvaline 
and canavanine 
Chelators for Fe"+; dehydroproline-containing 
polypeptides; poly-(L-proline); some divalent 
cations 
Chelators 
Chela tors; some divalent cations 
Co"+; free gal-O-hylys; UDP-gal analogues 
Tunicamycin 
/1-agonists; phosphodiesterase inhibitors 
S-S reducing agents 
Proline analogues; inhibitors of prolyl 4-hydrox­
ylase 
Colchicine, cytochalasin B, vinblastine; inhibi­
tors of triple-helix formation; some local an­
esthetics 
Several amino acids, polyamines, and their ana­
logues; synthetic peptides containing the 
cleavage sequence; chelators of CaH 
Nitriles; chelators of Cu2+ 
Glycemic control 
Inhibitors of procollagen to collagen conversion 
D-penicillamine; inhibitors of lysyl oxidase 
None known 
None known 
Inhibited by chelators of Ca2+, diphenylhydan­
toin, glucocorticoids, retinoids, a2-macroglob­
ulin, tissue polypeptide inhibitors; activated 
by sulfhydryl reagents, chao tropic agents, pro­
teolytic activators, monocyte factors 
Chelators of Ca2+; S-S reducing agents 
" These are the major steps in the sequence they are likely to occur under physiologic conditions in vivo; some of the reactions can, however, 
occur simultaneously or in reverse order (see reference 75). 
enzymes �1l,12]. The final degradation products, consisting of 
short pep tides and free amino acids, are excreted in the urine 
or they are metabolized in the liver [l3]. 
From the outline presented above, it is evident that both the 
biosynthesis and degradation of collagen involve multiple steps, 
many of which are enzymatically catalyzed (Table I). This 
situation then presents various levels of collagen metabolism 
which are potentially amenable to modulation by pharmaco­
logic agents. 
PHARMACOLOGIC AGENTS INTERFERING WITH 
COLLAGEN METABOLISM 
Modulators of Transcription and Translation 
Since the transcriptional and translational events during the 
biosynthesis of pro collagen are similar to those in general 
protein synthesis, several agents interfering with protein syn­
thesis at these levels could also modulate collagen production, 
but most of these agents would not be specific for collagen. 
There are suggestions that some pharmacologic compounds, 
such as glucocorticosteroids, tend to exert both catabolic and 
anabolic actions specific for collagen. Several studies employing 
tissue explants or intact animals have demonstrated that col­
lagen production is decreased in the presence of glucocortico­
steroids [14,15]. The inhibition of collagen has been shown to 
be more pronounced than the effects on protein synthesis in 
general. It has been also observed that fluorinated steroids are 
more potent inhibitors of collagen synthesis than nonfluori­
nated compounds [16]. These observations would be compatible 
with clinical findings of dermal atrophy induced by cortico­
steroid therapy [17,18]. They would also provide an explanation 
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FIG 1. Schematic presentation of the biosynthesis of pro collagen 
and the assembly of the collagen molecules into extracellular fibers. 
Abbreviation: mRNA, messenger RNA; aa's, amino acids; Hypro, hy­
droxyproline; Hylys, hydroxylysine; Glc-Gal, glucosylgalactose at­
tached to a hydroxylysyl residue; S-S bonds, disulfide bonds; lys, lysine; 
NH, ,amino terminal end of the newly-synthesized polypeptide chain, 
and also the E-amino group of either a lysyl or hydroxylysyl residue 
(reproduced with permission from Uitto, Ryhiinen, and Tan [3]). 
for the loss of collagen which accompanies intralesional steriod 
injection for treatment of keloids and hypertrophic scars [19]. 
It has been more difficult to define the mode of action of 
glucocorticosteroids in cell culture systems. In fact, the results 
from studies employing human skin fibroblast cultures have 
been contradictory in that both increased and decreased 
amounts of collagen have been obtained with cells cultured 
under apparently similar conditions (see reference 20). It ap­
pears that the contradictory results can be explained, at least 
in part, by the experimental tissue culture variables which 
include the type and concentration of the steroid used. Some 
trends are evident, however: In general, the halogenated ste­
roids at high concentrations tend to be inhibitory for collagen 
synthesis. Another general trend has been observed: The stud­
ies demonstrating depressed collagen production have mostly 
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TABLE II. Characteristics of enzymes participating in the 
biosynthesis and degradation of collagen 
Enzyme(/ Substrate" Product Co-Factors and Co-Substrates 
1. Signal pep- Nascent pre- pro-a chains None known 
tidase pro-a chains 
2. Prolyl-4-hy- Prolyl residue 4-hydroxypro- O2, Fe'+, a-keto-
droxylase in pro-gly se- line gl u tara te, as-
quence in corbic acid 
pro-a chains' 
3. Prolyl-3-hy- Prolyl residue 3-hydroxypro- 0" Fe2+, a-keto-
droxylase in pro-hyp- line glutarate, as-
gly sequence corbic acid 
in pro-a 
chains' 
4. Lysyl hy- Lysyl residue hydroxylysine O2, FeH, a-keto-
droxylase in lys-gly, glutarate, as-
lys-ser or lys- corbic acid 
ala-sequence 
in pro-a 
chains' 
5. Collagen Hydroxylysine gal-O-hydroxy- Mn'+, UDP-ga-
galactosyl in pro-a lysine lactose 
transfer- chains' 
ase 
6. Collagen Galactosyl-O- glc-gal-O-hy- Mn2+, UDP-glu-
glucosyl hydroxyly- droxylysine cose 
transfer- sine in pro-a 
ase chains' 
7. Protein di- Cystine resi- S-S-bonds sta- Thiols 
sulfide dues in the bilizing the 
isomer- extensions of correct pro-
ase( pro-a chains tein confor-
mation 
8. Pro collagen Procollagen or pC-collagen or Ca2+ 
N-termi- pN-collagen collagen" 
nal pro-
teinase 
9. Procollagen Pro collagen or pN -collagen or Ca2+ 
C-termi- pC-collagen collagen" 
nal pro-
teinase 
10. Lysyl oxi- Lysyl or hy- Aldehyde de- Cu�+, O<! 
dase droxylysyl rivatives of 
residue in fi- lysine and 
brillar colla- hydroxyly-
gen sllle 
11. Collagenase Specific se- Cleavage prod- Ca2+ 
quencesin ucts TCA and 
native colla- TCB 
gen 
12. Extracellu- Denatured col- Small peptides Ca2+ 
lar metal- lagenous and free 
lopro- polypeptides amino acids 
teinases 
13. Hydroxy- Free hydroxy- �'pyrroline-3- 0, 
proline proline hydroxy-5-
oxidase carboxylic 
acid 
14. Hydroxyly- Free hydroxy- O-phosphohy- Mg2+, GTP 
sine ki- lysine droxylysine 
nase 
"The action of these enzymes is relatively specific to collagen; the 
complete sequences of pro collagen synthesis and collagen degradation 
involve additional, less specific enzymes, such as those of transcription 
and translation. 
"The reactions indicated by an • are terminated when the pro-a 
chains fold into the triple helical conformation. 
,It has not been established whether the formation of interchain 
disulfides in pro collagen involves enzymatic catalysis, as occurs in some 
other proteins, or whether their synthesis takes place spontaneously. 
d If intact procollagen is used as a substrate, partially modified 
products are formed; however, if the partially cleaved proteins serve as 
substrates, collagen is produced. 
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FIG 2. Schematic presentation of cleavage of a collagen molecule by 
a specific collagenase and subsequent degradation of the cleavage 
products by other proteases into small pep tides and free amino acids. 
Abbreviations: H2N-, the amino-terminal ends of collagen a-chains; 
Tn" 1 he temperature at which the triple helical structure of collagenase 
cleavage products is denatured into nonhelical pep tides. Te' and TeB 
refer to the amino-terminal and carboxy-terminal fragments represent­
ing 3/4 and 1/4 lengths of the collagen molecule, respectively, obtained 
by the specific cleavage with a collagenase; upon denaturation, TCA 
and TCB yield individual polypeptides aA and a" (reproduced with 
permission from Uitto, Ryhiinen, and Tan [31). 
utilized adult skin fibroblasts, while those showing enhanced 
collagen synthesis have employed fetal cells [20]. 
Careful analyses of the in vitro data obtained with human 
skin fibroblasts in culture do not present any unifying hypoth­
esis or plausible explanation for steroid-induced dermal atro­
phy. While glucocorticoids appear to suppress collagen produc­
tion, it is equally feasible that collagen degradation may be 
enhanced in the presence of steroids [21]. Although the knowl­
edge of collagen degradation under normal conditions is less 
complete than that of collagen synthesis [22], the glucocorti­
costeroids appear to depress, rather than enhance, the activity 
of collagenase in human skin fibroblast cultures [23]. Thus, the 
variables involved in skin fibroblast cultures do not lend this 
system amenable to modulation by steroids. Hopefully, a com­
bination of in vivo and in vitro studies, taking into account the 
interactions of collagen with other connective tissue macromol­
ecules, may prove more fruitful in understanding the mecha­
nisms of steroid-induced dermal atrophy. 
The mechanisms by which other hormones may affect the 
metabolism of collagen have not been specifically delineated. 
Nevertheless, these hormones may dramatically alter the 
amounts of collagen in tissues [13,24,25]. For instance, in the 
case of hyperthyroidism, the synthesis of collagen is decreased; 
concomitantly, the degradation of collagen is increased. Hence, 
the net accumulation of collagen, as a result of these two effects, 
is depressed. Conversely, in hypothyroidism, the rate of synthe­
sis as well as the rate of degradation is diminished. Parathyroid 
hormone promotes the resorption of bone which is accompanied 
by an increase in the degradation of collagen fibers in bone 
matrix; these effects are opposed by calcitonin. The effects of 
other hormones are even less well-defined. It has been reported 
that large doses of estrogen decrease the rate of collagen re­
sorption. Growth hormone, on the other hand, increases colla­
gen synthesis, but because of the remodeling of connective 
tissues as they enlarge, there is also an increase in collagen 
degradation. The metabolism of collagen is clearly altered in 
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diabetes, but it is unclear whether the changes are due to insulin 
or whether they are mediated by fluctuations in glycemic 
conditions [26,27]. 
Another feasible control of excessive collagen deposition may 
evolve from studies demonstrating a feed-back inhibition of 
collagen production on the translational level. It has been 
suggested that the extension pep tides after their removal from 
procollagen are capable of inhibiting the synthesis of collagen 
polypeptides. Specifically, addition of isolated amino-terminal 
extension pep tides of type I procollagen inhibits the synthesis 
and secretion of pro collagen by cultured skin fibroblasts [27]. 
Furthermore, these peptides, when added to a cell-free trans­
lation system producing type I procollagen, depress the synthe­
sis of collagen [28]. Although the details and rationale of this 
kind of feed-back inhibition are still poorly understood [3], it is 
possible that synthetic peptide analogues of the pro collagen 
extensions can be developed for pharmacologic use. 
Inhibitors of Co- and Post-translational Modification 
Reactions 
During its intracellular biosynthesis, the newly-synthesized 
pro collagen polypeptides undergo several co- and posttransla­
tional modifications which could serve as sites of modulation of 
the collagen production. In particular, the enzymatic synthesis 
of 4-hydroxyproline has been shown to be crucial for normal 
collagen production; with reduced amounts of 4-hydroxyproline, 
the pro-a chains do not fold into a stable triple-helical confor­
mation at body temperature [30]. Since the triple-helix is pre­
requisite for collagen secretion at an optimum rate, the nonhel­
ical polypeptides, which are deficient in 4-hydroxyproline, first 
accumulate intracellularly and are subsequently released into 
the extracellular milieu at a markedly reduced rate [31,32]. 
Furthermore, the nonhelical pro-a chains are susceptible to 
proteolysis by both intracellular and extracellular proteinases. 
Thus, inhibition of prolyl hydroxylase could reduce the depo­
sition of collagen in tissues. 
Prolyl hydroxylase requires ferrous iron for its activity. Based 
on this observation, in early in vitro studies the synthesis of 
hydroxyproline was inhibited by metal chelators. Extensive 
studies have been performed, for example, with a,a'-dipyridyl, 
a chelator which is relatively specific for ferrous iron [30,33]. 
Although this compound has been proven to be highly effective 
in limiting the collagen synthesis by isolated tissues or cells in 
vitro, it has not been used in whole animals. It is possible that 
a,a' -dipyridyl, like other chelating agents, may be toxic due to 
inhibition of other vital enzymes which are dependent on metal 
co-factors. 
Another approach to inhibit the hydroxylation of prolyl 
residues has employed divalent cations, such as Zn2+, Pb2+ and 
C02+ (34,35). These metals compete with Fe2+ for prolyl hy­
droxylase, but they are unable to serve as cofactors in the 
hydroxylation reaction [35]. As a consequence, the procollagen 
polypeptides are underhydroxylated and retained intracellu­
larly in a similar manner as with a,a' -dipyridyl. In the case of 
Zn2+, the effective concentrations are in the physiologic range; 
it has been suggested that the tissue levels of zinc could mod­
ulate collagen metabolism and may have significance in path­
ologic fibrogenesis or play a role in its prevention [35]. 
An additional promising method to inhibit the synthesis of 4-
hydroxyproline in collagen, involves the use of a proline ana­
logue, 3,4-dehydroproline [36,37]. This analogue is readily in­
corporated into proteins in place of proline and this incorpora­
tion can have several consequences. In the case of pro collagen 
polypeptides, it has been demonstrated that the overall hy­
droxylation is drastically reduced and the pro-a chains remain 
nonhelical [38]. The inhibition of prolyl hydroxylation by this 
particular amino acid analogue can be explained by tight com­
plex formation between the analogue-containing polypeptides 
and prolyl hydroxylase [36]; as a consequence, the enzyme is 
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rendered nonfunctional. It should be noted that this effect of 
3,4-dehydroproline is not shared with other analogues of pro­
line, such as cis-4-hydroxyproline or L-azetidine-2-carboxylic 
acid, which destabilize the collagen triple helix by mechanisms 
independent of prolyl hydroxylation (see below). It is conceiv­
able that administration of dehydroproline or dehydroproline­
containing small molecular weight peptides could be used in 
the future to reduce collagen deposition in vivo. 
Inhibition of Procollagen Secretion 
Following the extensive intracellular modifications, the pro­
collagen molecules fold into a triple-helical conformation and 
are then secreted into the extracellular space [30]. The intra­
cellular translocation of procollagen involves the Golgi appa­
ratus; the protein packaged in Golgi vesicles is transported to 
the plasma membrane by energy-dependent mechanisms, 
which can be inhibited by microtubule or microfIlament dis­
rupting agents, such as colchicine, cytochalasin B, and vinblas­
tine [30,39]. It is conceivable, therefore, that these agents, or 
other microtubule disrupting compounds, could be employed 
for pharmacologic inhibition of collagen accumulation. In fact, 
colchicine has been used to counteract collagen deposition in 
animal models of liver cirrhosis and pulmonary fibrosis [40, 
41]. Furthermore, it has been suggested that colchicine might 
be helpful in the treatment of patients with progressive systemic 
sclerosis [42]. An additional rationale for the use of colchicine 
in fibrotic processes comes from the demonstration that colchi­
cine increases the release of collagenase by cells [43]. Thus, as 
a net result of decreased collagen secretion and increased deg­
radation mediated by collagenase, the collagen deposition 
would be reduced. At this point, however, the experience with 
the human subjects is rather limited and rigorous documenta­
tion of the beneficial effects of colchicine is still lacking. 
It is of interest that collagen secretion by cultured cells can 
also be modified by local anesthetics, such as procaine and 
lidocaine [44]. In contrast to colchicine, these compounds do 
not directly interact with microtubules or depolymerize them, 
but they have been suggested to detach the microtubular sys­
tem from the plasma membrane [44]. 
Inhibitors of Collagen Cross-linking 
Following the secretion, the procollagen molecules are con­
verted proteolytic ally to collagen by the removal of extension 
peptides (see below). The collagen molecules then align in a 
fibril structure in a characteristic quarter-stagger arrangement 
(Fig 1). The fibril structures are subsequently stabilized by the 
formation of covalent cross-links [45]. In the absence of cross­
linkage, the fibers lack the tensile strength necessary for func­
tional connective tissues. In addition, the uncross-linked colla­
gen molecules are more susceptible to degradation by collagen­
ases [46]. Thus, in the absence of cross-link formation, the net 
deposition of collagen is diminished. 
The synthesis of collagen cross-links is initiated by the con­
version of some lysine and hydroxylysine residues to corre­
sponding aldehydes. This reaction is catalyzed by lysyl oxidase, 
a copper-requiring extracellular enzyme [47,48]. The activity of 
lysyl oxidase is readily inhibited by nitriles, such as ,B-amino­
propionitrile, and these compounds have been widely tested in 
several animal models of tissue fibrosis. The results indicate 
that the accumulation of collagen is successfully prevented by 
these compounds. Additionally, encouraging preliminary results 
have been obtained in limited clinical trials in patients with 
urethral strictures, tendon adhesions and pulmonary fibrosis 
(see reference 49). The usefulness of the nitriles in generalized 
fibrotic conditions, such as progressive systemic sclerosis, re­
mains to be tested. 
Another pharmacologic agent which interferes with collagen 
cross-link formation is D-penicillamine. Its mode of action in 
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cross-linking is varied; first, D-penicillamine is a chelator of 
copper and thus reduces the activity of lysyl oxidase. It has also 
been shown that copper is required for the synthesis of lysyl 
oxidase protein, and in copper deficiency, less lysyl oxidase is 
functional in tissues [50]. Secondly, it has been shown that D­
penicillamine is able to complex with lysine-derived aldehydes 
making them unavailable for cross-link formation [51]. As a net 
result of these effects, newly-synthesized collagen remains sol­
uble and is degraded more rapidly, thus contributing to reduced 
collagen content in tissues. D-penicillamine has been employed 
for treatment of collagen accumulation diseases, such as hepatic 
fibrosis, progressive systemic sclerosis, and morphea. In the 
case of both systemic and localized scleroderma, some success 
has been reported [52,53], but the evaluation of the full benefits 
of D-penicillamine in these conditions would require controlled 
clinical trials with larger patient population. 
Modulation of Collagen Degradation 
The net amount of collagen in tissue is a balance between 
synthesis and degradation. Although in most fibrotic conditions, 
such as progressive systemic sclerosis, the collagen deposition 
is due to increased synthesis rather than decreased degradation, 
in a case of localized plantar fibromatosis, the collagen accu­
mulation has been shown to result from reduced collagenase 
activity [54]. In this and other fibrotic conditions, it would thus 
be helpful to induce collagenase activity which would facilitate 
the removal of excess collagen. Unfortunately, no pharmaco­
logic agent has been successful as yet in increasing the colla­
genase activity in vivo. However, under in vitro conditions, 
several factors, including sulfhydryl reagents, chaotropic agents 
and proteolytic treatments, have been shown to activate pre­
existing latent collagenase [9,55]. In addition, an immunologic 
factor, purified from monocyte cultures, has been demonstrated 
to stimulate the production of collagenase by cultured synovial 
cells [56]. It is conceivable, therefore, that these developments 
could form a basis for collagenase induction by pharmacologic 
means and such agents would be beneficial for patients with 
fibrotic processes. 
In contrast to collagenase induction and activation, this en­
zyme can be readily inhibited by several compounds, some of 
which are important in the treatment of human diseases. In 
particular, diphenylhydantoin has been shown to be beneficial 
in treatment of patients with recessive dystrophic epidermolysis 
bullosa, and its clinical efficacy has been suggested to involve 
inhibition of collagenase [57]. The drug is probably not a direct 
inhibitor of collagenase activity, but it reduces the production 
of enzyme protein by fibroblasts [57]. It should be noted that 
diphenylhydantoin may have multiple effects on collagen me­
tabolism, and thus its effects on connective tissue are probably 
complex. 
In addition to diphenylhydantoin, other pharmacologic 
agents have been shown to suppress the production of collagen­
ase in tissue culture situations. For example, glucocorticoste­
roids, such as hydrocortisone or dexamethasone, are capable of 
inhibiting collagenase in human skin explant cultures [23,58]. 
In contrast, some studies have suggested that collagen degra­
dation may increase in the presence of glucocorticosteroids 
[29]. Nevertheless, it is currently unknown if any change in 
collagenase activity does occur in patients undergoing treat­
ment with glucocorticosteroids. 
More recently, it has been demonstrated that retinoids, both 
naturally occurring tretinoin and synthetic isotretinoin, sup­
press the activity of collagenase in synovial cell cultures [59]. It 
was postulated that the inhibition was due to suppression of 
the synthesis of collagenase protein. Similar inhibition of col­
lagenase activity has also been noted in human skin fibroblast 
cultures, but here the inhibition was suggested to be due to 
increased synthesis of an inhibitor of collagenase activity [23]. 
Nevertheless, in the future, retinoids may provide a means to 
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modulate collagenase activity in patients whose disease involves 
abnormalities in collagen degradation. 
MODULATION OF COLLAGEN PRODUCTION BY NEW 
APPROACHES WITH AMINO ACIDS AND THEIR 
ANALOGUES 
Inhibition of Collagen Production By Proline Analogues 
An interesting and potentially specific way to interfere with 
collagen accumulation in tissues would be intracellular inhibi­
tion of the triple-helix formation. One of the recent develop­
ments involves the use of proline analogues for this purpose. 
Several structural analogues of proline, e.g., cis-4-hydroxy-L­
proline (cis-hydroxyproline), L-azetidine-2-carboxylic acid (aze­
tidine carboxylic acid), 3,4-dehydroproline, cis-4-bromo-L-pro­
line, and cis-4-fluoro-L-proline, have been shown to be incor­
porated in place of proline into proteins (see reference 38). The 
incorporation of these analogues into polypeptides can dramat­
ically alter the structure and metabolism of the protein. Incor­
poration of the analogues into collagen, a protein relatively rich 
in imino acids, proline and trans-4-hydroxy-L-proline (hydrox­
yproline), has been demonstrated to have several consequences: 
For example, the newly-synthesized polypeptides of procollagen 
do not fold into a stable triple helical conformation if a critical 
number of prolyl residues has been replaced by the analogue 
(Fig 3) [60,61]. Since the triple helical conformation is a prereq­
uisite for normal secretion of procollagen, the non-helical pro­
(\' chains are extruded from the cells into the extracellular milieu 
at a markedly reduced rate [62]. The nonhelical polypeptides 
are also susceptible to degradation by intracellular as well as 
extracellular proteinases which do not degrade triple-helical 
collagen. Consequently, the net production of extracellular col­
lagen is decreased in the presence of the analogues (Fig 3) [63] 
. Recent studies have also demonstrated that incubation of 17-
day-old chick embryo tendon fibroblasts in primary culture 
with cis-hydroxyproline results in an inhibition of growth of 
these cells [64]. Subsequently, it was also shown that this 
analogue retards the spreading and proliferation of normal 
murine connective tissue cells, but not of their counterparts 
rendered tumorigenic by viral, chemical, or spontaneous trans­
formation. [65] On the basis of the latter observations, it was 
suggested that the inhibition of the growth of normal cells by 
the analogues could be explained by the deficient production of 
extracellular collagen which may be required to support cell 
spreading and growth. 
We have recently extended the previous observations made 
on the proline analogues in animal systems to human skin 
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FIG 3. Schematic presentation of how cis-hydroxyproline and other 
proline analogues may reduce the production of extracellular collagen. 
The newly synthesized pro-a chains of procollagen containing the 
analogue (X) are unable to fold into a stable triple helical conformation 
and therefore are not secreted into the extracellular milieu at a normal 
rat�. Instead, the nonhelical pro-a chains are degraded, and the short 
breakdown products, even after transport into the extracellular space, 
are unable to form collagen fibers. 
Vol. 79, Supplement l 
fibroblast cultures. The experiments were designed to provide 
answers to the following questions: 
1. Is the production of pro collagen reduced in the presence 
of the analogues, and if so, does the inhibition occur on the 
transcriptional, translational, or posttranslational level? 
2. Do the analogues interfere with the attachment and pro­
liferation of cells, and if so, is the effect dependent on reduced 
collagen production by the cells? 
3. Could proline analogues potentially serve as pharmaco­
logic agents limiting collagen deposition in various forms of 
dermal fibroses? 
The results indicated that azetidine carboxylic acid markedly 
reduced the production of extracellular procollagen by normal 
skin fibroblasts. Examination of the procollagen production by 
the cells at different levels of protein synthesis and degradation 
indicated that the site of inhibition of collagen production 
occurred at the posttranslational level. Specifically, the tran­
scription of the procollagen genes into mRN A was not affected, 
since the mRNA activity, measured by cell-free translation in 
a rabbit reticulocyte lysate system, was the same in cells incu­
bated without and with the analogue [66]. Also, the transla­
tional rate of procollagen polypeptides in the cells was only 
slightly decreased, if the values were corrected for changes in 
the specific radioactivity of prolyl-tRNA complexes, the im­
mediate precursor of peptide-bound proline in the molecule 
[67]. In contrast, significant increases in the degradation of 
newly-synthesized collagen polypeptides, measured as the frac­
tion of CH} hydroxyproline in dialyzable form, were noted 
[66]. The increased posttranslational degradation of the ana­
logue-containing peptides, which have been previously [38,61] 
shown to be in a nonhelical conformation, probably reflects 
intracellular degradation of collagen. As a consequence, the net 
production of extracellular collagen is inhibited (Fig 3) . 
In further studies, we examined the effects of 2 of the proline 
analogues, cis-hydroxyproline and azetidine carboxylic acid, on 
the growth characteristics of human skin fibroblasts in culture 
[66]. The results indicated that the proliferation of the cells was 
markedly reduced in the presence of the analogues. The attach­
ment of the cells on the plastic substratum was also decreased, 
perhaps explaining, at least in part, the compromised growth 
potential. The inhibition of cell growth was achieved with 
analogue concentrations which were considerably lower than 
those affecting the collagen metabolism. Thus, the compro­
mised growth potential is probably not a consequence of re­
duced collagen production, as has been suggested previously 
[65]. Rather, the reduction in the rate of proliferation and 
attachment of the fibroblasts may reflect altered functions of 
other pericellular or cell membrane proteins which have incor­
porated the analogue. 
In these studies, we have also cultured fibroblasts from the 
skin of patients with active scleroderma; previously these cells 
have been shown to produce procollagen at an increased rate 
[68,69]. Incubation of the scleroderma fibroblasts with azetidine 
carboxylic acid reduced the production of extracellular procol­
lagen as was observed with control cells [57]. Recent studies, 
employing animal models of pulmonary fibrosis and liver cir­
rhosis have demonstrated the effectiveness of cis-hydroxypro­
line a�d azetidine carboxylic acid in reducing the accumulation 
of collagen when administered systemically [70,71]. It is con­
ceivable, therefore, that development of proline analogues could 
potentially provide us with the means to reduce the excessive 
accumulation of collagen in human tissues. 
Inhibition of the Conversion Of Pro collagen to Collagen by 
Amino Acids, Polyamines, or Their Structural Analogues 
Another level for potential inhibition of collagen deposition 
in tissues is the conversion of pro collagen to collagen. This 
conversion is a prerequisite for proper alignment of the collagen 
molecules to form fibers and for subsequent stabilization of the 
fiber structures by covalent cross-links (Fig 1). It has been 
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recently shown that argmme and its analogue, canavanine, 
inhibit the removal of the carboxy-terminal extension from type 
I procollagen [72]. As an extension of these observations, we 
have recently examined the effects of a variety of amino acids, 
polyamines, and their structural analogues on the conversion of 
type II pro collagen to collagen using pulse-chase techniques 
[73]. The results clearly demonstrate that several amino acids 
interfere with the conversion of type II pro collagen to collagen 
in short-term organ cultures (Fig 4). Specifically, ,a-alanine, 
arginine, asparagine, glutamine, hydroxylysine, lysine and or­
nithine inhibit the removal of carboxy-terminal extension from 
type II procollagen. We further demonstrated that several 
naturally occurring polyamines, such as agmatine, cadaverine, 
putrescine, and spermine likewise inhibit the conversion of pC­
collagen to collagen. In addition, a lysine analogue, S-2-amino­
ethylcysteine, as well as canavanine, are inhibitory. Finally, E­
aminocaproic acid, a well known inhibitor of proteinases causes 
the accumulation of pC-collagen in tissues [73]. 
The common structural feature of all the inhibitory com­
pounds is the presence of a free terminal amino group or amide. 
It is clear, however, that an a-amino group is not a sufficient 
structural feature to make a compound an inhibitor, since 
several a-amino acids, including alanine, glycine, isoleucine, 
leucine, phenylalanine, threonine, tryptophan, and valine, were 
not effective in our test system. 
The mechanisms of the inhibition of procollagen conversion 
by the compounds tested by us are not entirely clear at present. 
It has been suggested that arginine might prevent the removal 
of the carboxy-terminal extension by interfering with the aggre­
gation of procollagen molecules [72]. Alternatively, there could 
be a direct inhibition of the procollagen C-proteinase. In our 
study, we were able to inhibit the removal of the carboxy­
terminal extension with several compounds, including E-ami­
no caproic acid, a well known proteinase inhibitor. These results 
thus suggest that the interference with conversion may be a 
result of direct inhibition of procollagen C-proteinase. 
The results of these studies suggest novel approaches to 
control the collagen deposition in pathologic fibrotic conditions. 
Potentially, administration of nontoxic compounds containing 
the appropriate structural features and available in a form 
which would allow achievement of effective tissue concentra-
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FIG 4. Inhibition of conversion of type II pC-collagen to collagen 
by varying concentrations of cadaverine, lysine, E-aminocaproic acid, 
and {l-alanine. 17-Day-old chick embryo sterna were pulse-labeled for 
30 min with [14C ]proline, and the protein synthesis was inhibited by 
the addition of unlabeled proline and cycloheximide. The test com­
pounds were then added in concentrations indicated; at the end of the 
180-min chase period,  the ['·C]proteins were examined by SDS-poly­
acrylamide gel electrophoresis and quantitated by scanning the fluo­
rographs, as described in reference 73. The relative distribution of pC­
collagen is expressed as [ ' 4C]pC-a-chains as percent of the sum of [ ' 4C] 
pro-a, [ '4C]pC-a, [ '4C]pN_a, and [ ' 4C]a-chains. Symbols: 0- --0, ca­
daverine; __.., lysine; e- - -e, E-aminocaproic acid; 0--0, {l-alanine 
(reproduced with permission from Ryhiinen et al [73] ) .  
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tion." would lead to accumulation of pC-collagen. Since pC­
collagen is not capable of forming fibers of ordinary tensile 
strength, these poorly cross-linked molecules would probably 
be degraded by tissue collagenases at an accelerated rate. 
Similar approaches have been recently suggested by the use of 
synthetic peptides which interfere with the enzymatic conver­
sion of pro collagen to collagen [74]. 
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